Sienna Biopharmaceuticals (SNNA) Announces Quarterly Earnings Results, Misses Estimates By $0.10 EPS
Sienna Biopharmaceuticals (NASDAQ:SNNA) posted its quarterly earnings results on Thursday. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.10), MarketWatch Earnings reports.
SNNA opened at $2.54 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 4.86 and a current ratio of 4.86. Sienna Biopharmaceuticals has a 1 year low of $2.05 and a 1 year high of $21.53. The company has a market cap of $54.12 million, a P/E ratio of -0.49 and a beta of 3.66.
SNNA has been the topic of several recent research reports. Zacks Investment Research upgraded Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, December 19th. ValuEngine lowered Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Cowen set a $45.00 price target on Sienna Biopharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 3rd. Finally, BMO Capital Markets reduced their price target on Sienna Biopharmaceuticals from $27.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 4th.
COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2019/03/15/sienna-biopharmaceuticals-snna-posts-earnings-results-misses-estimates-by-0-07-eps.html.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Recommended Story: What are retained earnings?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.